Hypoxia is a condition commonly found in a wide-range of solid tumors and is often associated with tumor metastasis, therapy resistance and poor prognosis. Hypoxia-inducible factors, especially HIF-1α, are the central transcriptional regulators for genes involved in angiogenesis, metastasis and therapy resistance of tumor cells. Thus, targeting the HIF-1α pathway has been considered an attractive anticancer strategy. Here, we have found that cellular exposure to mitoxantrone (MX), or its derivatives, resulted in a reduction in the protein level of HIF-1α. Surprisingly, our data suggests that MX inhibits HIF-1α translation in a novel way that is independent of its topoisomerase II-targeting activity. While MX has already been approved for clinical use as an anticancer chemotherapy due to its excellent topoisomerase II-targeting activity, our results suggest that the dual activity of MX might offer a more efficacious therapeutic outcome and provide a rationale to further develop MX derivatives as anticancer agents. 
Introduction
Almost all types of solid tumors encounter a hypoxic microenvironment, a major factor in limiting tumor growth (1, 2) . It is generally believed that tumor cells escape from and/or adapt to this unfavorable growth condition mainly through the master regulators, hypoxia-inducible factors (HIF) (2) (3) (4) . For example, HIF-1 is a transcription factor that controls gene expression of over one hundred genes whose products have roles in angiogenesis, glycolysis, survival and cell death (4-6).
HIF-1 over-expression in tumors is clinically associated with treatment failure, therapy resistance and poor prognosis with conventional therapies including chemotherapy and radiotherapy (1, 3, (5) (6) (7) (8) . In animal models, HIF-1 activation has been shown to promote tumor growth, angiogenesis and metastasis, whereas loss of function of HIF-1 causes suppression of the above mentioned tumor propensities (2, 8) . Thus, HIF-1 has recently been considered a promising target for anticancer treatment and combination therapy.
HIF-1 is a hetero-dimeric transcription factor composed of two subunits, HIF-1α and HIF-1β.
Interestingly, while HIF-1β is constitutively expressed, HIF-1α is tightly regulated by changes in cellular oxygen tension (9) . Under normoxia, HIF-1α is degraded rapidly by the proteasome pathway through hydroxylation of proline residues 402 and/or 564 by prolyl hydroxylases (PHD1/2/3) and subsequent ubiquitylation mediated by the von Hippel-Lindau (pVHL) E3 ligase complex. FIH (Factor Inhibiting HIF-1) can hydroxylate HIF-1α at asparagine 803, which, in turn, blocks the recruitment of the co-activator p300/CBP and results in HIF-1α transcriptional inactivation. Under conditions of hypoxia, where hydroxylases are inactivated, the HIF-1α protein is stabilized and it translocates into the nucleus to form an active complex with HIF-1β (10) . In addition, growth factors and cytokines can stimulate HIF-1α protein synthesis via the phosphatidylinositol 3'-kinase (PI3k)/Akt pathway (6, 11, 12) .
Over the past few years, numerous studies have been performed to search for effective HIF inhibitors. Many novel compounds and known anticancer drugs have been shown to inhibit HIF-1α by reducing its transcriptional activation, stability and translation (4, 8, 11) . Interestingly, in addition to the clinically useful topoisomerase I (TOP1)-targeting topotecan, the TOP2-targeting agent NSC 644221 has been reported to inhibit HIF-1α protein synthesis (13, 14) . This suggests an additional anticancer activity of topoisomerase-targeting drugs through inhibition of HIF-1α. Interestingly, the MX-mediated inhibition of HIF-1α accumulation was largely independent of TOP2. We then further presented evidence that MX inhibited translation of HIF-1α, possibly at the elongation step. These findings identify MX as a potential candidate for the development of HIF-1α inhibitors and raising the potential implications of using MX to target HIF-1α in cancer cells.
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Materials and Methods

Cell lines and reagents
Human renal (769-P) and colorectal carcinoma (HCT116) cell lines were obtained from Drs. J-Y Lin (National Taiwan University, NTU; Taiwan) and B. Vogelstein (Johns Hopkins University, USA), respectively. Cells were cultivated in DMEM media supplemented with 10% fetal bovine serum, penicillin (100 units/ml), streptomycin (100 µg/ml) and glutamine (2 mM) in a 37 o C incubator with 21% O 2 and 5% CO 2 for normoxia. The hypoxic treatment was achieved by maintaining cells at 37 o C in a hypoxia incubator (ASTEC) with 5% CO 2 , 1% O 2 and 94% N 2 .
The pHA-HIF-1α plasmid was a gift from Dr. L. E. Huang (University of Utah, USA). All chemicals were obtained from Sigma-Aldrich unless indicated elsewhere. ICRF-193, mitoxantrone (MX) and its derivatives were synthesized by Dr. L-W Hsin (NTU) (15, 16) .
Immunoblot analysis
Cells were seeded in 6-well plates at 0. 
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA, isolated using Trizol reagent or PureLink™ RNA Mini Kit (Invitrogen), was reverse transcribed with random primers and SuperScript III reverse transcriptase (Invitrogen).
The cDNA pools were amplified using a 96-Well Thermal Cycler (Applied Biosystems) with the following primers (MB Mission Biotech): 5'-CTGGATGCTGGTGATTTGGA-3' and 5'-TTCATATCCAGGCTGTGTCG-3' for HIF-1α; 5'-GGGCCTCCGAAACCATGA AC-3' and 5'-TCCTCAGTGGGCACACACTC-3' for VEGF-A; 5'-GCTGGAAGGTGGACAGCGAG-3' and 5'-TGGCATCGTGATGGACTCCG-3' for β-actin, as a normalization control. The RT-PCR products were separated on a 2% agarose gel and visualized after ethidium bromide staining using a BioDoc-It imaging system (UVP). GCCCAAGTGTTCTTTAGCTTT-3'), TOP2β (5'-CCTGTGGTTATTCCAAGAGAT-3') or luciferase (as the negative control, 5'-CTTCGAAATGTCCGTTCGGTT-3'). After a 12-day selection with puromycin (1 µg/ml), the knockdown efficiency of pooled clones was determined by immunoblot analysis.
In vitro transcription and translation
The in vitro transcription and translation of HIF-1α was achieved using 1 µg of pHA-HIF-1α
plasmid DNA and the TNT® T7 Quick Coupled Transcription/Translation System (Promega) in the presence of methionine according to the manufacturer's protocol. After incubation at 30 o C for 90 min, reaction mixtures were assayed by immunoblot analysis. To decouple transcription from translation, pHA-HIF-1α (1 µg) was first transcribed using T7 RNA polymerase (NEB) at 37 o C for a 2-hr incubation. RNA transcripts were isolated by PureLink™ RNA Mini Kit and then treated with DNase I (NEB). The translation reactions were then performed as described above using HIF-1α mRNA.
Isolation of polysome-associated mRNA
The polysome analysis of 769-P cells was performed as described (17) . Briefly, cycloheximide (CHX, 100 µg/ml) was added to the cultures 10 min prior to harvesting. Cell pellets were washed twice with 1 X ice-cold PBS containing CHX, suspended in RSB buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 1.5 mM MgCl 2 and 1 mM DTT) supplemented with 250 U RNaseOUT (Invitrogen) and lysed in extraction buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 1.5 mM MgCl 2 , 1% Triton X-100, 1% deoxycholate and 2% Tween 20). After being centrifuged at 10,000 xg for 10 min at 4 o C, each supernatant was layered onto a continuous 5 ml of a 10-50% sucrose gradient (in 10 mM
Tris-HCl pH 7.4, 75 mM KCl and 1.5 mM MgCl 2 ). Fractionation was achieved with a 2-hour centrifugation using the Beckman SW41 rotor at 36,000 rpm at 4 o C. The polysomal profile was then monitored at 254 nm in an ISCO UA-6 absorbance detector. The polysomal and nonpolysomal fractions were collected and subjected to mRNA isolation using PureLink™ RNA Mini Kit.
Research.
on 
MX inhibits HIF-1α protein accumulation in a concentration-and time-dependent manner
Exposure of 769-P cells to MX for 6 hours at a concentration of greater than 5 µM prominently inhibited the hypoxia-induced expression of HIF-1α ( Fig. 2A) . In figure 2B , HIF-1α was detectable at 2 hours, reached maximum detection at four to 6 hours and then decreased slightly at 8 hours under hypoxia. MX effectively inhibited HIF-1α expression at all time-points examined.
In the clinic, MX-based therapy is administered intravenously at a dose of 10 -14 mg/m 2 , with a peak plasma concentration at approximately 1.0 µmol/L (20) (21) (22) . Because HIF-1α proteins are almost undetectable under prolonged hypoxia (16 hours) (23, 24) , the effect of low concentrations of MX on HIF-1α expression during prolonged hypoxia was addressed with proteasome inhibition.
As expected, proteasome inhibition by MG-132 or Velcade led to significant accumulation of HIF-1α under prolonged hypoxia ( Supplementary Fig. S2 ). This accumulation was attenuated with 0.5 µM of MX, which is approximately half of the clinical concentration.
Inhibition of HIF-1α expression by MX is largely independent of both TOP2 isozymes
MX is a well-known TOP2-targeting drug (25) (26) (27) . Two TOP2 isozymes are found in human (Fig. 3A) . Moreover, ICRF-193 co-treatment did not interfere with the inhibitory ability of MX on HIF-1α expression. We then compared the MXmediated inhibition on HIF-1α expression in the parental HL-60 and TOP2-deficient HL-60/MX2 cell lines (28, 29) in the presence and absence of MG-132 (10 μM). Despite slight differences in HIF-1α protein levels and mobility in control cells, HIF-1α expression is completely inhibited by MX in both cell lines (Supplementary Fig. S3A ). To further examine the involvement of TOP2 isozymes, we generated the isozyme-specific knockdown cell lines by infecting 769-P and HCT116 cells with lentiviral particles expressing shRNA specifically against TOP2α or TOP2β.
Despite the excellent knockdown efficiencies, knockdown of either TOP2 isoform had only minimal effects on the inhibitory ability of MX on HIF-1α expression (Fig. 3B) . Similarly, this was observed in HL-60 cells with individual isozyme knockdown ( Supplementary Fig. S3B ).
Because the simultaneous knockdown of both isozymes confers a great disadvantage in growth (30, 31) and the surviving cells are often those with poor knockdown efficiencies (data not shown), we could only establish the double knockdown in HCT116 and HL-60 cells. Consistent with the notion that the MX-mediated reduction of HIF-1α accumulation is largely TOP2-independent, the inhibitory effect of MX on HIF-1α expression was not compromised in cells deficient of both isozymes ( Fig. 3C and Supplementary Fig. S3C ).
MX does not affect degradation of HIF-1α protein but induces expression of HIF-1α mRNA
HIF-1α is rapidly degraded through the proteasome pathway under normoxia (3, 11) . Reduction of HIF-1α expression by MX in the presence of proteasome inhibitors strongly suggests that inhibition of HIF-1α accumulation by MX is independent of the proteasome (Fig. 4A ). HIF-1α possesses an oxygen-dependent degradation domain (ODD) rendering HIF-1α unstable in the presence of oxygen; thus, deletion of the ODD domain (△ODD) enables HIF-1α to escape oxygen-driven degradation (32) . We transfected cells with plasmid constructs expressing HAtagged HIF-1α or HA-HIF-1α-△ODD and showed that MX treatment reduced the accumulation of both HIF-1α and HIF-1α-△ODD ( Supplementary Fig. S4 ), ruling out the involvement of oxygen-driven degradation in the inhibitory effect of MX.
Next, we measured HIF-1α stability in the presence or absence of MX after blocking de novo protein synthesis with cycloheximide (CHX). Cells were placed under hypoxia for 2 hours to accumulate HIF-1α protein. This was followed by a 1-hour treatment with MX, and addition of CHX (20 µg/ml) to monitor the decay of HIF-1α. HIF-1α declined rapidly, even in the presence of We further examined whether HIF-1α and VEGF-A mRNA synthesis was affected by MX treatment using reverse transcription-PCR (RT-PCR) with quantitative analysis. RNA levels of VEGF-A, a HIF-1α target-gene, decreased significantly when MX was added (Fig. 4C) , supporting the hypothesis that MX inhibits the transcriptional activation ability of HIF-1α. In contrast, HIF-1α mRNA was slightly increased after MX treatment. Together, the above findings suggest that MX does not inhibit HIF-1α expression through protein degradation or inhibition of transcription, raising the possibility that MX reduces HIF-1α expression via inhibition of translation of HIF-1α mRNA.
MX inhibits translation of HIF-1α
A shift in the balance between protein synthesis and degradation can also result in a reduction of HIF-1α protein accumulation (11, 12) . To investigate this possibility, we treated 769-P cells with CHX which resulted in HIF-1α becoming undetectable within 2 hours after treatment (Fig.   5A ). After pre-treatment for 2 hours with CHX in normoxia, cells were washed and replenished with drug-free media. A total of 5 μM MX was then added under hypoxia to investigate the effect of MX on HIF-1α protein translation. Compared to the untreated control cells, the level of newly synthesized HIF-1α was largely reduced with MX treatment (Fig. 5B, compare lane 5 to 6 ).
Unlike the proteasome inhibitor MG-132, which caused HIF-1α accumulation, both MX and CHX decreased HIF-1α expression (Fig. 5C , compare lane 4, 5, 6 and 7). In addition, HIF-1α and VEGF-A mRNA levels changed similarly after MX and CHX treatments (Fig. 5D ).
To confirm that MX impairs the translation of HIF-1α, in vitro synthesis of HIF-1α was performed and showed that MX suppressed protein synthesis of HIF-1α in a concentrationdependent manner (Fig. 6A) . To further ascertain that MX exerts its action at the translational level, HIF-1α mRNA was first transcribed in vitro, purified and added to the translation reactions.
In this setting, protein synthesis of HIF-1α was still strongly repressed by MX (Fig. 6B) . Thus, the above results suggest that MX impairs the translation step of HIF-1α expression. Recent studies have shown that the PI3K/Akt/mTOR pathway regulates HIF-1α expression at the translational level (6, 11, 12 Figs. S4A-B) . These results suggest that the action of MX is different from that of rapamycin. Since transfection of constitutively active Akt could not reverse MX-mediated inhibition of HIF-1α expression (Supplementary Figs. S5C-D) , the involvement of Akt was also ruled out.
To gain more insight into the MX-mediated translational inhibition of HIF-1α expression, we examined HIF-1α mRNA associated with polysomes. Compared to control, MX treatment caused a collapse of the polysomes, while CHX treatment displayed only a slight decrease in the 80S peak and polysomes (Fig. 6C) . We then analyzed the HIF-1α mRNA in the non-polysomal and polysomal fractions and found that treatment with either MX or CHX led to a significant increase of HIF-1α mRNA in the polysomal fractions (Fig. 6D, upper panel) . This increase suggests a defect in translation elongation in the presence of MX. Consistent with the notion that MX inhibits HIF-1α function, the polysome-associated VEGF-A mRNA levels were reduced in the presence of MX compared to that of untreated control (Fig. 6D, lower panel) . 
Discussion
MX belongs to the clinically useful TOP2-targeting anthraquinones that are used to treat metastatic breast cancer, leukemia and lymphoma (22, 27, 33) and it is one of the drugs approved for multiple sclerosis (34) . To our knowledge, this is the first report of MX as an inhibitor of HIF-1α. In corroboration with other studies (13, 35, 36) As for the underlying mechanism(s) of the MX-mediated inhibition of HIF-1α expression, our results indicate the potential involvement of translational inhibition. HIF-1α is known to be primarily regulated at the level of protein stability in which the PHD and proteasome pathways cause the rapid degradation of HIF-1α under normoxia (10) . We have shown that MX inhibits HIF-1α protein accumulation in a proteasome-independent manner and does not change the protein half-life. Moreover, our observation that MX inhibits HIF-1α accumulation in the presence of hypoxia mimetics argues against the degradation of HIF-1α though the oxygen-dependent PHD pathway. Similarly, the ability of MX to inhibit the accumulation of a mutant HIF-1α lacking the oxygen degradation domain implies a mechanism other than oxygen-dependent degradation. The tumor suppressor p53 has also been implicated to negatively regulate expression of HIF-1α (12) . When activated by DNA damaging agents, p53 can accelerate degradation and down-regulate translation of HIF-1α (37) (38) (39) . Indeed, we found that p53 was activated after MX treatment (data not shown). In addition, MX inhibited HIF-1α expression in the matched HCT116 p53
-/-and shp53
on (41, 42) and has been shown to stabilize the tau pre-mRNA stem-loop structure and alter tau mRNA splicing by intercalating between two G-C base pairs (43) . The secondary structure predicted by RNA-fold software reveals many G-C base pairs in HIF-1α mRNA, which supports the possibility that MX may intercalate into HIF-1α mRNA. This interaction might impede the migration of ribosomes and hence inhibit translation of HIF-1α.
Resistance to therapy remains a main obstacle in clinical interventions for cancer patients.
After radiation therapy HIF-1α is activated in surviving cancer cells and accelerates radioresistance by promoting angiogenesis (44) (45) (46) . HIF-1α inhibition has been shown to restore sensitivity to therapy (45) (46) (47) (48) , and YC-1 and PX-478 are thought to enhance the efficacy of radiation therapy by inhibiting HIF-1α (44, 49) . Moreover, daunorubicin and DOX can inhibit HIF-1α activity (with no effect on HIF-1α accumulation) and cause a reduction in tumor vascularization in animal models (35 expression is largely independent of TOP2α and TOP2β. Cells were first infected with lentiviruses expressing shRNAs targeting TOP2α (shTOP2α) or TOP2β (shTOP2β) or control luciferase (shLuc). After a 12-day selection with puromycin (1 µg/ml), the MX-mediated inhibition of HIF-1α expression in pooled clones was determined. 
Figure legends
